296 related articles for article (PubMed ID: 31713445)
1. Inotersen therapy of transthyretin amyloid cardiomyopathy.
Dasgupta NR; Rissing SM; Smith J; Jung J; Benson MD
Amyloid; 2020 Mar; 27(1):52-58. PubMed ID: 31713445
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
3. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
Benson MD; Dasgupta NR; Monia BP
Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
[TBL] [Abstract][Full Text] [Related]
5. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
6. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
[TBL] [Abstract][Full Text] [Related]
7. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
[TBL] [Abstract][Full Text] [Related]
8. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
Narayanan P; Curtis BR; Shen L; Schneider E; Tami JA; Paz S; Burel SA; Tai LJ; Machemer T; Kwoh TJ; Xia S; Shattil SJ; Witztum JL; Engelhardt JA; Henry SP; Monia BP; Hughes SG
Nucleic Acid Ther; 2020 Apr; 30(2):94-103. PubMed ID: 32043907
[TBL] [Abstract][Full Text] [Related]
9. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Mathew V; Wang AK
Drug Des Devel Ther; 2019; 13():1515-1525. PubMed ID: 31118583
[TBL] [Abstract][Full Text] [Related]
10. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen.
Dasgupta NR; Benson MD
Amyloid; 2019; 26(sup1):20-21. PubMed ID: 31343363
[No Abstract] [Full Text] [Related]
11. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
12. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
Mahfouz M; Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
[TBL] [Abstract][Full Text] [Related]
13. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
15. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
Coelho T; Yarlas A; Waddington-Cruz M; White MK; Sikora Kessler A; Lovley A; Pollock M; Guthrie S; Ackermann EJ; Hughes SG; Karam C; Khella S; Gertz M; Merlini G; Obici L; Schmidt HH; Polydefkis M; Dyck PJB; Brannagan Iii TH; Conceição I; Benson MD; Berk JL
J Neurol; 2020 Apr; 267(4):1070-1079. PubMed ID: 31853709
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
17. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA; Mauermann ML; Grogan M; Coelho T
Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
[TBL] [Abstract][Full Text] [Related]
19. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
20. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
Conceição I
Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
